Please provide your email address to receive an email when new articles are posted on . The FDA has approved obecabtagene autoleucel for the treatment of adults with relapsed refractory B-cell ...
The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...
Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...
Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.
Pediatric Acute Lymphoblastic Leukemia: Clinical Characteristics, Treatment Outcomes, and Prognostic Factors: 10 Years' Experience From a Low- and Middle-Income Country A retrospective cohort study ...
The FDA has granted approval to a larger vial size of nelarabine injection (SH-111) for use in treatment of adult and ...
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
Hosted on MSN
Major treatment overhauls for acute myeloid leukemia
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Subscribe to ...
NEWS AT SIX. THERE IS NEW HOPE FOR CHILDREN AND ADULTS WITH LEUKEMIA, A LIFE SAVING DRUG IS CHANGING THE GAME FOR TREATING THE DISEASE. AND A KCCI INVESTIGATES REPORT. LAURA TERRELL LEARNED DOCTORS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results